
KCK Group is a multi-billion AUM single-family office based in New York, managing assets for the Kassar family. The firm operates through multiple investment vehicles — including KCK Financial Services (fintech/financial services) and KCK Medtech (medical devices) — investing across life sciences, energy, industrials, and financial services from early-stage to growth and public companies.
47% of their portfolio is in Healthcare. Average disclosed round size is $57.1M (across 19 rounds with reported amounts).
Portfolio
14
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
19 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Series C | $70M | Feb 2023 | |
| Series D | $95M | May 2021 | |
| Series B | $128M | Jan 2021 | |
| Growth | $48M | Aug 2020 | |
| Unknown | $67M | Jan 2020 | |
| RRefleXion | Series A | $100M | Jan 2020 |
| Series A | $11.6M | Jan 2020 | |
| Growth | $70M | Dec 2019 | |
| Series C | $30M | Dec 2019 | |
| Series D | $31M | Sep 2019 | |
| Series B | $30M | Sep 2018 | |
| Series A | $30M | Jun 2016 | |
| Series B | $46M | Apr 2016 | |
| Series B | $46M | Apr 2016 | |
| Growth | $100M | Jan 2016 | |
| Series C | $51M | Jun 2013 | |
| Series B | $20M | — | |
| Series C | $100M | — | |
| Series A | $11.6M | — |
Top Co-Investors
Venrock7 shared
Sofinnova Partners7 shared
Pfizer Ventures7 shared
T. Rowe Price4 shared
Bain Capital Ventures3 shared
Winklevoss Capital Management3 shared
Polychain Capital3 shared
Founders Fund3 shared
Exor Ventures2 shared
Upper902 shared
OrbiMed2 shared
Ally Bridge Group2 shared
Lightrock1 shared
Standard Industries1 shared
General Catalyst1 shared
Devonshire Investors1 shared
ClearSky1 shared
Equinor1 shared
Khosla Ventures1 shared
Chevron Technology Ventures1 shared
Last updated: 8 September 2026